Amino acid-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  L-Serine, Epicatechin and Matrine (SEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 21/March/2018, 1.53 pm

 Molecular therapy for inflammation and arthritis: Monascin, a secondary metabolite derived from Monascus purpureus-fermented products, increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 21/March/2018, 1.47 pm
March 21, 2018
Molecular therapy for diabetes (TIDM): Ankaflavin, a secondary metabolite produced by yeast monascus purpureus, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 21/March/2018, 2.07 pm
March 21, 2018

Comments are closed.